Jiuqiang Biotech (300406): 24H1 operating side is under pressure to further improve profitability
Jiuqiang Biotech (300406): Strong business growth, optimistic about demand recovery in the second half of the year+acceleration of national reform
Jiuqiang Biotech (300406): Sinopharm's investment plan to continue to increase the IVD platform is beginning to take shape
Jiuqiang Biotech (300406): Sinopharm empowers the steady development of established IVD companies to reduce costs and increase efficiency
Jiuqiang Biotech (300406): Sinopharm's shareholding ratio continues to increase, demonstrating confidence in the company's development and recognition of value
Jiuqiang Biotech (300406) 2024 Quarterly Report Review: Further Improving Profitability, Platform Construction Continues to Advance
Pacific released a research report on April 8, stating that Jiujiang Biotech (300406.SZ) was given a purchase rating. The main reasons for the rating include: 1) full recovery of outpatient and surgical volumes in medical institutions, driving growth in b
Jiuqiang Biotech (300406) Annual Report Review: Steady Performance Growth, Sinopharm Empowers Marketing Efficiency
Jiuqiang Biotech (300406) 2023 Report Review: Strong 23Q4 performance, Sinopharm continues to advance
Jiuqiang Biotech (300406): Performance is in line with expectations and continues to be optimistic about pathology business+Sinopharm empowerment
Jiuqiang Biotech (300406)'s wholly-owned subsidiary invests abroad in Xiamen Longjin Biotechnology Co., Ltd. announcement comment: Acquiring part of Longjin Biotech's shares to build a platform-based enterprise
Jiuqiang Biotech (300406): Acquired leading FISH track company Longjin Biotech to jointly enhance overall competitiveness
Jiuqiang Biotech (300406): Multi-end layout such as biochemistry and pathology empowers state-owned assets to inject growth momentum
Comment on the resolution announcement of the fourth meeting of the fifth board of directors of Jiuqiang Biology (300406): Clarifying strategic development ideas and seizing opportunities for Chinese medicine to empower Chinese medicine
Jiuqiang Biotech (300406): New Product Outbound, New Breakthrough, New Layout of the Glowing Track
Jiuqiang Biology (300406): Sinopharm empowers progress towards a platform-based IVD company
Jiuqiang Biotech (300406) 2023 Interim Report Review: Significant recovery in performance, cooperation empowers the company's long-term growth
Jiuqiang Biology (300406): Diagnostic demand is recovering well and optimistic about the transformation of platform-based IVD companies
九强生物(300406):上半年业绩略超预期 持续看好平台化IVD企业转型
九强生物(300406):疫后修复成效显著 Q2业绩超预期
No Data